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Cardiomyocyte proliferation accounts for the increase of cardiac muscle during
fetal mammalian heart development. Shortly after birth, cardiomyocyte transits from
hyperplasia to hypertrophic growth. Here, we have investigated the role of fatty
acid β-oxidation in cardiomyocyte proliferation and hypertrophic growth during early
postnatal life in mice. A transient wave of increased cell cycle activity of cardiomyocyte
was observed between postnatal day 3 and 5, that proceeded as cardiomyocyte
hypertrophic growth and maturation. Assessment of cardiomyocyte metabolism in
neonatal mouse heart revealed a myocardial metabolic shift from glycolysis to fatty acid
β-oxidation that coincided with the burst of cardiomyocyte cell cycle reactivation and
hypertrophic growth. Inhibition of fatty acid β-oxidation metabolism in infant mouse
heart delayed cardiomyocyte cell cycle exit, hypertrophic growth and maturation.
By contrast, pharmacologic and genetic activation of PPARα, a major regulator of
cardiac fatty acid metabolism, induced fatty acid β-oxidation and initially promoted
cardiomyocyte proliferation rate in infant mice. As the cell cycle proceeded, activation
of PPARα-mediated fatty acid β-oxidation promoted cardiomyocytes hypertrophic
growth and maturation, which led to cell cycle exit. As a consequence, activation of
PPARα-mediated fatty acid β-oxidation did not alter the total number of cardiomyocytes
in infant mice. These findings indicate a unique role of fatty acid β-oxidation in regulating
cardiomyocyte proliferation and hypertrophic growth in infant mice.
Keywords: fatty acid oxidation, cardiomyocyte, proliferation, hypertrophic growth, infant mice
INTRODUCTION
Cardiac myocytes constitute the most fundamental functional units of the heart. Mammalian
cardiomyocytes proliferate rapidly and use glycolysis as the main source of energy during fetal
life (Lopaschuk et al., 1991; Soonpaa et al., 1996; Li et al., 1997b). After birth, cardiomyocytes
exit cell cycle and transit from hyperplasia to hypertrophic growth (Li et al., 1997a). Over the
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first week of postnatal life in mice, cardiomyocytes
exhibit a transient wave of increased cell cycle activity
(Lopaschuk et al., 1991; Soonpaa et al., 1996; Li et al., 1997a,b),
that proceeds as cardiomyocyte binucleation, cell size
enlargement and a metabolic switch from glycolysis to fatty
acid β-oxidation (Lopaschuk and Spafford, 1990; Li et al., 1997a;
Makinde et al., 1998; Ahuja et al., 2007; Naqvi et al., 2009;
Lopaschuk and Jaswal, 2010; Zebrowski and Engel, 2013).
However, it remains unknown whether the switch in
metabolic pathways controls cardiomyocyte proliferation
and hypertrophic growth.
There is a growing appreciation that metabolic signals
are integrated to cell cycle progression. In relatively simpler
cellular systems grown in tissue culture conditions where
nutrient supply could be tightly regulated, it is well established
that cell cycle progression is influenced by metabolites or
a combination of metabolites and an oscillating signal
(Tu et al., 2007; Buchakjian and Kornbluth, 2010; Mandal
et al., 2010; Lee and Finkel, 2013; Shi and Tu, 2013; Yalcin et al.,
2014; Papagiannakis et al., 2017). For instance, studies in the
growth of budding yeast show that metabolic intermediate,
acetyl-CoA, controls G1 phase progression. Subsequent analysis
of gene expression from chromatin immunoprecipitation
assay revealed that acetyl-CoA induces the acetylation of
histone in the growth genes and enables cell growth and
proliferation (Cai et al., 2011; Shi and Tu, 2013). Relevant
studies, using interventions that alter nutrient utilization,
show that oscillating metabolism of budding yeast determines
the timing of the cell-cycle phases and sets the pace of cell
division (Papagiannakis et al., 2017).
By contrast, little is known about whether and how metabolic
state of cardiomyocyte influences cell growth and division
in the complex mammalian heart. Cardiomyocytes in fetal
mouse hearts can proliferate quite dramatically and exit cell
cycle soon after birth (Soonpaa et al., 1996; Lopaschuk and
Jaswal, 2010). Recent studies show that the heart exhibits
a transient phase of cardiomyocyte cell cycle reactivation
during early postnatal life (Soonpaa et al., 1996). However,
postnatal cell cycle progression has several unique features
compared to that of fetal life. First, rather than generating
mononucleated cardiomyocytes, postnatal cardiomyocytes failed
to complete cell division, which results in the formation of
binucleated cardiomyocytes (Soonpaa et al., 1996; Li et al.,
1997b). Second, instead of maintaining constant cell volume,
postnatal cardiomyocytes exhibit hypertrophic growth (Li et al.,
1996). Cardiomyocyte binucleation seems to be closely related
with the onset of hypertrophy. Third, unlike proliferating
cardiomyocyte that use glycolysis as a source of energy in fetal
heart, fatty acid β-oxidation is the primary catabolic pathway that
provides energy needed for contractile function in early postnatal
hearts (Lopaschuk and Jaswal, 2010). Although a metabolic shift
from glycolysis to fatty acid oxidation has been described during
the first week of postnatal heart development in mice, it is unclear
whether this metabolic change accounts for cardiomyocyte
proliferation and hypertrophy or is simply a consequence of
increased O2 availability that coincides with transition from fetal
to postnatal life.
In this study, we investigated the cardiac metabolic state in the
developing cardiomyocyte during early postnatal life in mice, and
the role of fatty acid β-oxidation in cardiomyocyte proliferation
and the transition from hyperplasia to hypertrophy. In doing so,
we make important insights about the biological consequences of
alterations in energy metabolism on the growth of cardiac muscle.
MATERIALS AND METHODS
Animal Studies
CD-1 R© IGS mice were purchased from Charles River Laboratories
(Horsham, PA, United States). Generation and genotyping of the
αMHC-PPARα line has been previously described (Finck et al.,
2002). All litter sizes were adjusted as 8–10 pups per litter. The
sex of infant mice used in these studies was not determined.
In general, sample size was chosen to use the least number
of animals to achieve statistical significance and no statistical
methods were used to predetermine sample size. Animals were
allocated to experimental groups based on genotype and we did
not use exclusion, randomization or blinding approaches. All
the animal experiments were performed according to the NIH
guidelines (Guide for the care and use of laboratory animals).
All experimental procedures involving animals in this study were
reviewed and approved by Temple University Medical Center’s
Institutional Animal Care and Use Committee.
Neonatal Cardiomyocyte Isolation and
Culture
Mouse neonates (<10 days of age) were sacrificed by
decapitation. Cardiomyocytes were collected using previously
described protocol (Tian et al., 2015). Briefly, mouse
cardiomyocytes were isolated by enzymatic disassociation of
one day-old neonate hearts (P1). Cells were plated differentially
for 2 h to remove fibroblasts. Cardiomyocytes were plated on
laminin-coated (10 µg/cm2) 96-well plates at 1.5 × 104 cells per
well. On the following day, culture medium was replaced with
fresh medium (Opti-MEM supplemented with 10% fetal bovine
serum, 5% horse serum and 10 Unit/ml Penicillin-Streptomycin)
either with or without etomoxir (5 µM).
Immunostaining for cTnT in
Cardiomyocytes and Myocyte Size
Measurements
Isolated cells were fixed by 4% PFA at room temperature (r.t.) for
15 min. Fixed cells were pelleted, washed two times in 1 ml of PBS,
then re-suspended in permeabilization buffer at r.t. for another
15 min. Permeabilized cells were pelleted, washed two times in
1 ml of PBS, then processed for blocking and immunostaining
for cardiomyocyte marker (cTnT, 1:200; Thermo Fisher Scientific,
MS-295-P1). DAPI was used to counterstain nuclei. Images were
acquired for analysis within 48 h. Cell length and width were
determined from phase contrast images using the ImageJ plugin
Coli-Inspector. Length and width measurements from ≥ 300
cells from ≥ 3 biological replicates were used to generate data
for each condition.
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Histology
Neonatal and adult heart tissues were fixed in 2 and 4%
formaldehyde individually and processed for paraffin histology
and sectioned using routine procedures. Immunohistochemical
staining was performed using previously described protocol
(Tian et al., 2015). Primary antibodies are: Ki67 (1:50;
Abcam, ab16667), Phospho-Histone H3 (PH3, 1:200; Cell
Signaling Technology; 9706L), Aurora B kinase (1:200; BD
Transduction Laboratories; 611082), cardiac Troponin T (cTnT,
1:100; Thermo Fisher Scientific, MS-295-P1), cardiac Troponin I
(cTnI, 1:200; Abcam; ab47003), Caveolin-1 (1:100, Cell Signaling
Technology; 3238S), Wheat Germ Agglutinin (WGA), Alexa
Fluor R© 633 Conjugate was used on the same sections to
outline cardiomyocytes. DAPI was used to counterstain nuclei.
Apoptosis was measured using in situ Cell Death Detection
Kit (Roche). Cell proliferation was measured using Click-
iT R© EdU (5-ethynyl-2′-deoxyuridine) Alexa Fluor R© Imaging
Kit (Thermo Fisher Scientific). The slides were imaged and
subjected to an independent blinded analysis, using a Zeiss LSM
710 confocal microscope and ImageJ software. Images shown
are representative view of multiple fields from at least four
independent samples per group. Quantitation of cell numbers
was done using images acquired on confocal microscopy and
the ImageJ with the “Cell Counter” plug-in, counting multiple
fields from at least 4 independent samples per group and about
2200–5000 cTnT+ cells per sample.
In vivo Treatment and EdU Labeling
Infant mice were treated with etomoxir (15 µg/g/day; Sigma,
E1905) or GW7647 (2 µg/g/day; Sigma, G6793) or saline via
intraperitoneal (i.p.) injection on postnatal day 2 (P2), P3 and
P4, one dose per day. For EdU labeling, infant mice were injected
with one dose of EdU 50 mg/kg via intraperitoneal injection and
sacrificed after 3 h.
Extracellular Flux Measurements
Metabolic profiling was assessed performing glycolytic stress test
and palmitate oxidation test using a Seahorse XF flux analyzer
96. Cardiomyocytes were isolated from 8 to 10 infant mice
on day 2 (P2), 3(P3), 5 (P5), and 7 (P7) after birth. Cells
were seeded on Seahorse XF-96 plates coated with laminin at
a density of 4 × 104 cells/well and incubated for 24 h in
culture cells media. One day prior to the experiment, sensor
cartridges were hydrated with XF calibrate solution (pH 7.4)
and incubated at 37◦C in a non-CO2 incubator for 24 h. To
evaluate glycolytic function, culture medium was exchanged with
the XF Assay media (XF-base media supplemented with 2 mM
glutamine, pH7.4) and the microplates placed into a 37◦C non-
CO2 incubator for 1 h prior to the start of an assay. Extracellular
acidification rate (ECAR) was measured at baseline and after
the injection of glucose (10 mM), oligomycin (1 µM) and 2-
deoxyglucose (2-DG, 50 mM).
To evaluate the effect of etomoxir and GW7647 on
cardiomyocyte glycolytic function, we plated cardiomyocytes
isolated from P3 infant mice in the presence of etomoxir (5 µM)
or GW7647 (2 µM) for 24 h. On the next day, media was replaced
with XF Glycolysis Assay media and ECAR levels were measured
before and after the injection of Glucose (10 mM).
To assess fatty acid oxidation, endogenous substrates within
the cells were depleted replacing the culture media with
Substrate-Limited Media (D-MEM supplemented with 0.5 mM
Glucose, 1 mM GlutaMAX, 0.5 mM carnitine and 1% FBS)
and incubating the cells for an additional 24 h. One hour prior
to the assay, culture media was replaced to FAO assay media
(KHB supplemented with 2.5 mM glucose, 0.5 mM carnitine and
5 mM Hepes, pH was adjusted to 7.4). Oxygen consumption
rate (OCR) was measured at baseline and after the injection of
saturating amount of Palmitate-BSA (XF palmitate–BSA FAO
substrate, Seahorse bioscience, Agilent Technology) and two
doses of etomoxir (40 µM) to obtain the maximal inhibition
of exogenous Fatty acid oxidation. To assess glucose oxidation,
1 h prior to the assay, culture media was replaced to substrate-
free XF- Base media. OCR levels were measured at baseline
and after the injection of Glucose 10 mM and oligomycin
(2 µM). Three baseline measurements of ECAR and OCR
were taken before glucose or palmitate-BSA injection, and 3
response measurements were taken after the addition of each
other compound. ECAR and OCR were expressed as a percentage
of the baseline measurement. Glycolysis was quantified as the
maximum percentage increase of ECAR over baseline, after the
injection of saturating amount of glucose. Glycolytic capacity
defined as maximum obtainable glycolysis after inhibition of
mitochondrial ATP production was measured as maximum
percentage increase over baseline after oligomycin injection.
Glucose oxidation was measured as maximum percentage
increase over baseline after glucose and oligomycin injection.
β-oxidation was evaluated as maximum percentage increase over
baseline after palmitate-BSA injection.
Echocardiography
Mice were anesthetized with inhalation of isoflurane induction
3%, followed by maintenance at 2% using a nose cone. The mouse
was placed on a warm platform in the supine position to keep
the body temperature around 37◦C. The chest hair is removed
using hair removal gel cream (Nair). The limbs are taped onto
the metal EKG leads. Echo was performed using VisualSonic
Vevo 2100 system with a 40 MHz transducer for cardiac imaging.
In brief, by placing the transducer along the long-axis of LV,
and directing to the right side of the neck of the mouse, two-
dimensional LV long-axis is obtained. Then the transducer is
rotated clockwise by 90◦, and the LV short-axis view is visualized.
2D-guided LV M-mode at the papillary muscle level is recorded
from either the short-axis view and/or the long-axis view. Trans-
mitral inflow Doppler spectra are recorded in an apical 4-
chamber view by placing the sample volume at the tip of the
mitral valves. Echo images are downloaded and analyzed oﬄine
using images analyzing software (Vevo 2100, 1.70, VisualSonic).
At least three beats of imaging were measured and averaged for
the interpretation of any given measurement. End-diastolic and
end-systolic left ventricular internal diameters (LVIDd, LVIDs)
were measured from the left ventricular short axis view with 2D
orientated M-mode imaging. Left ventricular systolic function
was estimated by fractional shortening (FS, %) according to the
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following formula: FS (%) = [(LVIDd – LVIDs)/LVIDd] × 100.
Ejection fraction (EF) was calculated using the end-systolic and
end-diastolic volumes as described (Stypmann et al., 2009).
Cardiomyocyte Isolation From 3-Week
Old Mice
Mice (3-week old) were sacrificed by Avertin overdose followed
by cervical dislocation. Hearts were dissected. Ventricular
myocytes were isolated using a modified method of a previously
described protocol (Zhou et al., 2000). Briefly, excised hearts
were mounted on a Langendorf apparatus and perfused with
Ca2+-free Tyrode solution for 2 min at 37◦C, followed by
6–10 min of perfusion with the same Tyrode solution with
additional 20 µM CaCl2, 1 mg/ml collagenase (Worthington
type II), and 0.13 mg/ml trypsin. The ventricles were placed in
a plastic container containing 5 ml of same enzyme solution,
and cut into 4 pieces. Ventricular tissues were gently triturated
with a plastic transfer pipet to dissociate individual myocytes.
Non-cardiomyocytes were depleted by centrifugation at 200 g
for 30 s. Cardiomyocytes were re-suspended in the same Tyrode
solution with addition of 125 µM CaCl2 and 5 mg/ml BSA.
Cardiomyocytes were then pelleted at 200 g for 30 s and
fixed with 4% PFA.
RNA Purification and qRT-PCR Analysis
Quantitative real-time PCR (qRT-PCR) analysis was performed
using Trizol isolated RNA, which was used to generate
cDNA using random hexamer primers and SuperScript III
RT (Invitrogen). qRT-PCR primer sequences are listed in
Supplementary Table 1. SYBR green detection of amplification
was performed using the StepOne Plus cycler (Applied
Biosystems). Transcript expression values were generated with
the comparative threshold cycle (Delta CT) method by
normalizing to the expression of the 18S gene.
Statistical Analysis
Data are presented as mean± standard error of the mean (s.e.m.).
Student’s t-test, one-way ANOVA and two-way ANOVA were
used to calculate statistical significance. P values are depicted as
follows: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001.
Results with P > 0.05 were considered not significant (n.s.). All
analyses were performed with GraphPad Prism 7.
RESULTS
Cardiomyocytes Reactivate Cell Cycle
and Become Binuclear During Early
Postnatal Life
We measured total number of cardiomyocytes in the ventricular
myocardium by enzymatic disaggregation and direct cell
counting. The number of cardiomyocyte expanded continuously
between 1-day-old (P1) and P10 mice (Supplementary
Figure 1A). Notably, the rate of increase in cardiomyocytes
number was highest within the first 3 days of age, with a
28.8 ± 2.0% increase from P1 to P3 (P < 0.05) (Supplementary
Figure 1A). By contrast, the rate of increase was attenuated
after P3 and the number of cardiomyocytes remained relatively
constant between P3 and P5. This suggests a decline in
cardiomyocyte hyperplasia growth. To determine DNA
synthesis in cardiomyocytes, infant mice received a single
intraperitoneal injection of 5-ethyl-2′-deoxyuridine (EdU) and
were sacrificed after a 3-h labeling period. The frequency of
EdU incorporation was determined on isolated ventricular
cardiomyocyte by co-labeling with antibody against cardiac
troponin T (cTnT) (Figure 1A). Consistent with our observations
on cardiomyocytes number and previous reports (Soonpaa et al.,
1996; Walsh et al., 2010; Ikenishi et al., 2012; Hirai et al.,
2016), a transient increase of DNA synthesis was observed in
infant cardiomyocytes, with a peak labeling index of ∼10%
occurring between P3 and P5 (Figure 1B). The wave of increased
cardiomyocyte cell cycle progression was also observed by
immunostaining of sectioned hearts for EdU incorporation
and the mitotic cell cycle marker phosphorylated histone H3
(PH3). The levels of EdU+Caveolin1+ and PH3+cTnT+
were highest in P3–P5 hearts, followed by a significant drop
in P7 hearts (Supplementary Figures 1B,C). Accordingly,
the DNA synthesis rate in cardiomyocytes increased from
P1 to P5, reflecting the continuous progression of the cell
cycle wave, whereas the total number of cardiomyocytes
increased early but remained relatively constant from P3
to P5 (Supplementary Figure 1A). To determine whether
cell division changes during postnatal life, we calculated the
number of mono-, and bi-nuclear cardiomyocytes added
to the ventricles by multiplying the average cardiomyocyte
numbers by the percentages of cardiomyocyte that were
mononucleate, or binucleate at these time points. The most
striking change was the increase by (31.7 ± 1.2) × 104
binucleated cardiomyocytes (4.5 ± 0.01-fold increase) that
occurred from P3 to P5, followed by a further increase of
(33.3 ± 1.5) × 104 binucleated cardiomyocytes (1.8 ± 0.03-
fold increase) from P5 to P7 (Supplementary Figure 1C). By
contrast, (20.8 ± 0.9) × 104 mononucleated cardiomyocyte
(19.7 ± 0.1% decrease) were lost from P3 to P5. This is
followed by a further loss of (24.2 ± 1.6) × 104 mononucleated
cardiomyocytes (28.6 ± 0.7% decrease) that was observed
between P5 and P7 (Supplementary Figure 1D). Furthermore,
we measured the expression of several mitosis-promoting
genes in the cardiac ventricles from P1 to P10 and found
significant increases in mRNA levels of these genes in both
P3 and P5, with levels in P7 falling significantly compared to
those in P1 (Supplementary Figure 1E). These data support
the previous observations showing that the wave of postnatal
cardiomyocyte cell cycle reactivation, marked by increased
DNA synthesis, terminates before cell division and generates
cardiomyocyte binucleation (Soonpaa et al., 1996; Ikenishi et al.,
2012; Hirai et al., 2016).
Cardiomyocyte Hypertrophic Growth and
Maturation During Early Postnatal Life
We next assessed cardiomyocyte size as previously described
(Chen et al., 2007). Freshly isolated cardiomyocytes were fixed
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FIGURE 1 | Continued
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FIGURE 1 | Cardiomyocyte cycling and metabolic profiling in infant mouse cardiomyocytes. (A) Isolated cardiomyocytes in DNA synthesis-phase were visualized by
immunofluorescent microscopy using Click-iT EdU Alexa Fluor (red) and co-immunostaining with antibody against cardiac troponin T (cTnT, green). Arrows point to
EdU+cTnT+ cells. Arrowheads point to binuclear cTnT+ cells. (B) Quantification of EdU+cTnT+ cells as percentage of total cTnT+ cells (∼1200 cTnT+ cells per
sample). (C) Confocal images cardiomyocytes in mitotic phase as detected by co-immunostainings for phosphorylated histone H3 (PH3, red) and cTnT (green) on
tissue sections, and quantification of PH3+cTnT+ cells as percentage of total cTnT+ cells analyzed per field. Arrows point to PH3+cTnT+ cells. (D–G) Isolated
mouse cardiomyocytes from postnatal day 2 (P2), P5 and P7 heart ventricles were assessed with the Seahorse XF Analyzer. (D) Measurement and (E) quantification
of mitochondrial oxygen consumption rate (OCR) with fatty acid stress test using palmitate versus BSA control. (F) Measurement and (G) quantification of
extracellular acidification rate (ECAR) in the glycolysis stress assay. 2-DG (2-deoxyglucose) is a hexokinase inhibitor, which inhibits glycolytic pathway. P value was
calculated using one-way ANOVA.
prior to immunostaining for cTnT. Cells were then imaged and
surface area was assessed using Image J. There was a∼23.3± 4%
increase in the size of cardiomyocyte from P1 to P3 (P < 0.01,
Supplementary Figures 1F,G). Two dimensional surface area
was further increased from 226.3 ± 29.2 µm2 in cardiomyocyte
of P3 hearts to 347.12 ± 55.5 µm2 in the P5 hearts (53 ± 9%
increase, P < 0.001). Cardiomyocyte size was further increased
by 68.6 ± 8% in the P7 hearts (585.3 ± 41.9 µm2, P < 0.05,
Supplementary Figures 1F,G). This result is consistent with the
previous report that mammalian cardiomyocytes hypertrophic
growth postnatally (Li et al., 1996).
Gene expression analysis on isolated heart ventricles
showed that β-myosin heavy chain, Myh7 (a marker of fetal
cardiomyocytes) (Lyons et al., 1990; England and Loughna,
2013), mRNA decreased by ∼27% in P3 compared to P1 hearts
(P < 0.05), ∼42% in P5 compared to P3 hearts (P < 0.05), and
∼60% in P7 compared to P5 hearts (P < 0.05). By contrast,
Myh6 (a marker of general cardiomyocytes) mRNA levels
were not significantly changed (Supplementary Figure 1H).
Moreover, the expression of Mef2c and Nkx2.5, the genes
associated with fetal cardiomyocyte development (Olson,
2006; Li et al., 2016), followed the same pattern with Myh7
gene expression and decreased significantly from P1 to P7
(Supplementary Figure 1H). Collectively, these results showed
that the occurrences of cardiomyocyte hypertrophic growth
and maturation were in parallel with cardiomyocyte cell cycle
reactivation in infant mouse hearts.
Cardiomyocyte Cell Cycle Reactivation
and Hypertrophic Growth Are
Accompanied by Metabolic Switch to
Fatty Acid β-Oxidation
We used metabolic-flux analysis (with the Seahorse XF
Analyzer) to assess mitochondrial respiration and anaerobic
glycolysis by measuring the OCR and ECAR, respectively.
Fatty acid stress test using palmitate revealed that P5
and P7 cardiomyocytes have greater OCR increase in
response to palmitate than P2 cardiomyocytes (P < 0.01,
Figures 1D,E). By contrast, a significant decrease was observed
in the maximum ECAR in the glycolysis stress assay for
cardiomyocytes at P5 and P7 compared to cardiomyocytes at
P2 (Figures 1F,G). Together, these data suggest a shift away
from glycolytic metabolism and toward fatty acid β-oxidation
in infant cardiomyocytes between 2 and 5 days after birth,
coinciding with cardiomyocyte cell cycle reactivation and
hypertrophic growth.
Inhibition of Cardiomyocyte Fatty Acid
β-Oxidation Enhances Glycolysis and
Maintains the Ability of Cardiomyocyte
to Proliferate in Infant Mice
We administered etomoxir (ETO), an inhibitor of carnitine
palmitoyltransferase I (CPT1) (Lopaschuk et al., 1988), which
is a key regulator of mitochondrial fatty acid uptake, in
cultured neonatal mouse cardiomyocytes. A 48 h exposure of
cardiomyocytes to ETO (5 µM) increased ECAR compared
to untreated cardiomyocytes (Figure 2A), which indicates
enhanced glycolytic metabolism in cardiomyocytes. ETO-
treated cardiomyocytes exhibited higher proliferation index than
untreated cardiomyocytes, as shown by the numbers of Ki67 (cell
cycle marker) and cTnT (cardiomyocyte marker) double positive
cells (Ki67+/cTnT+) as well as Aurora B kinase (Auk, cytokinesis
marker) and cTnI (cardiomyocyte marker) double positive cells
(Auk+/cTnI+) (P < 0.01, Figures 2B,C).
Next, ETO was administered daily via intraperitoneal
injections into infant mice at P2, P3, and P4. Ventricular
cardiomyocytes were isolated at P5 and processed for Seahorse
analysis. ETO administration decreased OCR in response to
palmitate compared to saline-treated mice (Figures 2D–F).
Analyses of mouse heart ventricles by qRT-PCR showed that
ETO-treated mice had a significant decrease of fatty acid
metabolism-associated genes (PPARα, Acaca, Acacb, Cpt1b,
Acadm, Acadl) at P5 compared to the saline-treated mice
(Figure 2G). Furthermore, ETO-treated hearts had significantly
increased expression of pyruvate dehydrogenase kinase 4 (Pdk4),
which inhibits catabolism of the glucose-derived pyruvate
(Sugden and Holness, 1994) (Figure 2G). Analyses of glucose
oxidation showed that ETO administration decreased oxygen
OCR in response to glucose compared to saline-treated mice
(Figures 2H,I). These results indicate that in vivo treatment of
ETO reduced fatty acid β-oxidation and glucose oxidation in
infant mouse hearts.
To examine cell proliferation, infant mice, either treated
with ETO or saline at P2, P3, and P4, were pulsed with EdU
for 3 h at P5. Consistent with the in vitro observations, we
found that treatment with the ETO in vivo increased cell cycle
activity in cardiomyocytes (EdU+/cTnT+, PH3+/cTnT+,
Ki67+/cTnT+) (Figures 3A–C). To determine whether
cell division was altered in ETO-treated hearts, we isolated
cardiomyocytes from P5 heart ventricles and counted the
number of mononucleated and binucleated cardiomyocytes.
Notably, ETO treatment inhibited cardiomyocyte binucleation
prominence and resulted in a 31 ± 8.9% increase in total
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FIGURE 2 | Effects of etomoxir (ETO) and GW7647 treatment on cardiomyocyte metabolism. (A) Isolated neonatal mouse cardiomyocytes (P1) were cultured with
medium containing ETO (5 µM) for 48 h. ECAR was measured in cardiomyocytes using the Seahorse XF Analyzer. (B) Cardiomyocyte proliferation were visualized by
co-immunostaining for Ki67 (red) and cTnT (green) on cultured cardiomyocytes, and quantification of Ki67+cTnT+ as percentage of total cTnT+ cells analyzed.
Arrows point to Ki67+cTnT+ cells. (C) Cardiomyocytes in cytokinesis were visualized by co-immunostaining for Aurora B kinase (Auk, green) and cTnI (red) on
cultured cardiomyocytes, and quantification of Auk+cTnI+ as percentage of total cTnI+ cells analyzed. (D) Schematic of experimental design for experiments
performed in panels (E–I). Infant mice were treated either with ETO or GW7647 or saline at P2, P3, and P4. Cardiomyocytes were isolated at P5 and processed for
Seahorse analysis or gene expression analysis. (E,F) OCR was measured (E) and quantified in response to palmitate or BSA challenge (F). (G) Expression of
indicated genes by qRT-PCR analysis of the mRNA of isolated heart ventricles at P5 (n = 4–6 per group). (H,I) OCR was measured in isolated cardiomyocytes at P5
(H) and quantified in response to glucose challenge (I). P value was calculated using Student’s t-test (A–C, G) and one-way ANOVA (F, I).
number of cardiomyocytes compared to saline-treated mice
(Figures 3D,E). TUNEL staining of heart sections showed no
significant difference in the number of apoptotic cells between
ETO- and saline-treated heart at P5 (Figure 3F). Cardiac
expression of apoptosis-associated genes (Bax, Bcl2) was not
affected at P5 (Figure 3G).
Inhibition of Fatty Acid β-Oxidation
Delays Cell Cycle Exit, Hypertrophic
Growth and Maturation in Infant Mouse
Cardiomyocytes
To determine whether cardiomyocyte proliferation was
maintained at later stage, infant mice were treated with ETO at
P2, P3, and P4 and pulsed with EdU for 3 h at P7 (Figure 4A).
Increased DNA synthesis was continuously observed in
cardiomyocytes of P7 mice as determined by quantification of
the EdU+cTnT+ cells isolated from heart ventricles (1.76± 0.2-
fold higher in ETO-treated mice compared to saline-treated
group, P < 0.01, Figure 4B). There was a ∼53% reduction
in the percentage of binucleated EdU+cTnT+ cells in ETO-
treated hearts compared to saline-treated hearts (0.1 ± 0.01%
vs. 0.21 ± 0.11%, P < 0.05, Figure 4C). Furthermore, ETO
treatment led to a reduction in cardiomyocyte binucleation
compared to saline treatment (31 ± 1.6%, P < 0.01, Figure 4D).
These data indicated that ETO treatment maintained the ability
of cardiomyocyte to proliferate in infant mice.
Since cardiomyocyte proliferation is associated with the
onset of hypertrophic growth during early postnatal life (Li
et al., 1996), we examined the effect of ETO treatment on
the size of cardiomyocytes. Analysis of two dimensional
surface area of isolated cardiomyocytes from heart ventricles
revealed that cardiomyocytes from ETO-treated mice had
decreased cell surface area compared to those from saline-
treated mice (395.05 ± 55.5 µm2 vs. 585.28 ± 41.9 µm2,
P < 0.0001, Figure 4E). qRT-PCR analysis using isolated heart
ventricles at P5 from mice treated with ETO compared to
saline-treated mice showed significantly increased expression
of genes associated with positive regulation of cell proliferation
(Ccnd1, Ccnd2), as well as fetal cardiomyocyte program-
associated genes, including Myh7, Gata4, Mef2c, and Nkx2.5
(Figure 4F). These results indicated that ETO-mediated
inhibition of fatty acid β-oxidation reduced cardiomyocyte
hypertrophic growth and maturation. Because it has been
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FIGURE 3 | Cardiomyocyte proliferation with etomoxir (ETO) treatment. (A) Cardiomyocytes in DNA synthesis-phase were detected by using Click-iT EdU Alexa
Fluor (red) and co-immunostaining with antibody against cTnT (green) on tissue cross sections. Quantification of EdU+cTnT+ cells as percentage of total cTnT+ cells
analyzed per field. Arrows point to EdU+cTnT+ cells. (B) Cardiomyocytes in mitotic phase were detected and quantified by immunostaining for PH3 (red) and cTnT
(green) on tissue longitudinal sections. Arrows point to PH3+cTnT+ cells. (C) Cardiomyocyte proliferation were visualized by co-immunostaining of heart sections
(P5) for Ki67 (red) and cTnT (green). Graph on the right showing quantification of Ki67+cTnT+ as percentage of total cTnT+ cells analyzed per field. Arrows point to
Ki67+cTnT+ cells. (D) Percentage of mononuclear (Mono-CM) and binuclear (Bi-CM) cardiomyocytes in the heart ventricles of infant mice at P5. (E) Total number of
cardiomyocytes in heart ventricles in infant mice at P5. (F) Immunostaining and quantification of TUNEL (green) and DAPI (blue) in P5 heart sections. Arrows point to
TUNEL+ nuclei. (G) Expression of Bax and Bcl2 by qRT-PCR analysis of the mRNA of isolated heart ventricles at P5 (n = 4 per group). P value was calculated using
Student’s t-test (A–C, E–G) and two-way ANOVA (D).
shown that prolonged less maturation in cardiomyocytes
results in decreased cardiac function (Tian et al., 2015), we
performed an additional and separate blinded study to assess
whether the effects of ETO on the hearts could be resolved
at later time point. Those observations were completely
absent in P21 hearts, as the expression of those genes was
equivalent between saline and ETO-treated mice (Figures 4G,H).
Echocardiographic analysis showed normal cardiac function
in ETO-treated mice compared to the saline-treated mice
(Figure 4I). The ratio of heart weight to body weight was
similar between saline and ETO-treated mice (Figure 4J). The
size of ventricular cardiomyocytes isolated from ETO-treated
mice was similar to that of saline-treated mice (Figure 4K).
Moreover, cell cycle activity (EdU+/cTnT+, PH3+/cTnT+)
and binucleation were similar between ETO- and saline-treated
mice (Figures 4L,M).
Taken together, these results indicated that ETO-mediated
inhibition of fatty acid β-oxidation in infant mouse hearts
maintained the ability of cardiomyocyte to proliferate. However,
cardiomyocyte hypertrophic growth and maturation were
reduced upon ETO treatment. Those effects of ETO waned over
time, as seen by the similar level of cardiomyocyte cell cycle
activity, cell size and maturation in the hearts at weaning age.
We thus conclude that ETO-mediated inhibition of fatty acid
β-oxidation in infant mouse heart delayed cardiomyocyte cell
cycle exit and hypertrophic growth.
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FIGURE 4 | Cardiomyocyte size growth and maturation with etomoxir (ETO) treatment. (A) Schematic of experimental design for experiments performed in panels
(B–E). (B) Isolated cardiomyocytes in DNA synthesis-phase were visualized by immunofluorescent microscopy using Click-iT EdU Alexa Fluor (red) and
co-immunostaining with antibody against cTnT (green). Arrowheads point to EdU+cTnT+ cells. Quantification of EdU+cTnT+ cells as percentage of total cTnT+ cells
(∼940 cTnT+ cells per sample). Scale bars: 50 µm. (C) The percentage of mononucleated EdU+ cardiomyocytes (Mono-CM) and binucleated EdU+ cardiomyocytes
(Bi-CM) at P7. Arrowheads point to mononuclear EdU+cTnT+ cells. Arrows point to binuclear EdU+cTnT+ cells. Scale bar: 25 µm. (D) Percentage of mononuclear
(Mono-CM) and binuclear (Bi-CM) cardiomyocytes in the heart ventricles of infant mice at P7. (E) The frequency distribution and mean square areas of the surface
area of cardiomyocytes isolated from P7 mouse heart ventricles. (F) Expression of indicated genes by qRT-PCR analysis of the mRNA of isolated heart ventricles at
P5 (n = 5 per group). (G) Schematic of experimental design for experiments performed in panels (H–M). (H) Quantification of gene expression by qRT-PCR analysis
of the mRNA of isolated heart ventricles at P21 (n = 4 per group). (I) Cardiac function in mice evaluated by echocardiography at P21 (n = 4 per group). EF, ejection
fraction; FS, fractional shortening; EDV, end-diastolic volume; ESV, end-systolic volume. (J) Heart weight-to-body weight ratios at P21. (K) The frequency distribution
and mean square areas of isolated ventricular cardiomyocytes at P21. (L) Quantification of EdU+cTnT+ and PH3+cTnT+ as percentage of total cTnT+ cells analyzed
on heart sections at P21. (M) Percentage of mononuclear (Mono-CM), binuclear (Bi-CM) and multinuclear (Multi-CM) cardiomyocytes in the heart ventricles of adult
mice at P21. P value was calculated using Student’s t-test.
Activation of PPARα-Mediated Fatty Acid
β-Oxidation Promotes Cell Proliferation
Rate and Hypertrophic Growth, but Does
Not Alter Total Cell Numbers in Infant
Mouse Cardiomyocytes
To promote fatty acid β-oxidation, we treated infant mice via
intraperitoneal injections of GW7647, a highly specific PPARα
agonist that increases fatty acid uptake and β-oxidation (Kersten
et al., 1999). Using a similar approach as ETO treatment,
infant mice were treated with GW7647 at P2, P3 and P4, and
analyzed at P5 (Figure 2D). GW7647 administration significantly
increased OCR in response to palmitate challenge in the isolated
ventricular cardiomyocytes compared to saline-treated mice
(Figure 2E). Analysis of the expression of PPARα target genes
(Acaca, Acacb, Acadm, Acadl, Cpt1b), which regulate fatty acid
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FIGURE 5 | Cardiomyocyte proliferation and hypertrophic growth in GW7647-treated infant mouse hearts. (A) Infant mice were treated either with GW7647 or saline
at P2, P3 and P4. Quantification of genes associated with fatty acid metabolism by qRT-PCR analysis of the mRNA of isolated heart ventricles at P5 (n = 4 per
group). (B) Quantification of EdU+cTnT+ cells as percentage of total cTnT+ cells isolated from heart ventricles at indicated time points (n = 6 per group, ∼1000
cTnT+ cells per sample). (C) Quantification of total number of cardiomyocyte isolated from heart ventricles at indicated time points (n = 4–8 per group).
(D) Representative images of isolated cardiomyocytes from P5 heart ventricles and quantification of the percentage of mononucleated (Mono-CM) and binucleated
(Bi-CM) cardiomyocytes (n = 4–6 per group, ∼1000 cTnT+ cells per sample). Arrows point to Bi-CM. cTnT (blue). DAPI (gray). (E,F) Ventricular cardiomyocytes were
isolated at P5 and measured for surface area. Quantitative analyses represent frequency distribution (E) and mean square areas (F) of the surface area of
cardiomyocytes. (G) Quantification of genes associated with cardiomyocyte maturation by qRT-PCR analysis of the mRNA of isolated heart ventricles at P5 (n = 4–5
per group). P value was calculated using Student’s t-test (A, F,G), one-way ANOVA (D) and two-way ANOVA (B,C).
metabolism, by qRT-PCR showed a significant increase in the
hearts of GW7647-treated mice compared to those of saline-
treated mice (Figure 5A). Analyses of glucose oxidation showed
that there was no significant difference in OCR in response to
glucose between GW7647- and saline-treated cardiomyocytes
(Figures 2H,I). These results indicated that in vivo treatment
of GW7647 promoted fatty acid metabolism and β-oxidation in
infant mouse heart.
We next evaluated the effect of GW7647-mediated PPARα
activation on cardiomyocyte proliferation. Mice were pulsed
with EdU for 3 h before harvesting tissues. DNA synthesis
was quantified in isolated ventricular cardiomyocytes by
visualizing EdU labeled cells that were co-immunostained
with cardiomyocyte marker (cTnT). GW7647 treatment led
to increased number of cardiomyocyte incorporating EdU
(EdU+/cTnT+ cells) at P4 compared to saline or ETO treatment
(16.6 ± 1.1% vs. 10.45 ± 0.8% for saline or 11.06 ± 0.6%
for ETO, P < 0.001, Figure 5B). Quantification of the total
number of ventricular cardiomyocytes showed that GW7647
treatment led to a 24 ± 5.9% increase in the total number of
cardiomyocytes compared to saline or ETO treatment at P4
(P < 0.05, Figure 5C). However, the effect of GW7647 on
cardiomyocyte proliferation became reversed over time, as seen
by a quick fall in the number of EdU+/cTnT+ cells by P7 in
mice with GW7647 treatment at P2, P3 and P4 (Figure 5B).
Furthermore, the total number of cardiomyocytes was similar
between GW7647-treated heart and saline-treated heart at P7
(Figure 5C). To determine whether GW7647-mediated PPARα
activation affected cardiomyocyte hypertrophic growth and
maturation, we examined cardiomyocytes binucleation, cell size
and gene expression. Notably, the percentage of binucleated
cardiomyocytes at P5 was∼26% higher in GW7647-treated heart
than saline-treated heart (41.2± 0.7% vs. 32.5± 1.1%, P< 0.001,
Figure 5D). Assessment of cardiomyocyte size by quantifying
two-dimensional surface area of isolated cardiomyocytes from
P5 heart ventricles showed that GW7647 treatment led to
increased cardiomyocyte size compared to saline treatment
(472.6 ± 12.1 µm2 vs. 347.1 ± 16.9 µm2, P < 0.0001,
Figures 5E,F). qRT-PCR analysis showed GW7647-treated
hearts had a significant decrease in the expression of fetal
cardiomyocyte program genes (Myh7, Gata4, Mef2c, Nkx2.5)
compared with saline-treated hearts (Figure 5G), suggesting
enhanced cardiomyocytes maturation in GW7647-treated hearts.
In order to determine whether PPARα-mediated increase in
fatty acid β-oxidation controlled cardiomyocyte proliferation
and maturation in a cell-autonomous manner, we utilized a
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FIGURE 6 | Cardiomyocyte proliferation and hypertrophic growth in αMHC-PPARα transgenic (Tg) hearts. (A) Quantification of genes associated with fatty acid
metabolism by qRT-PCR analysis of the mRNA of isolated heart ventricles at P5 (n = 4 per group). (B) Quantification of EdU+cTnT+ cells as percentage of total
cTnT+ cells isolated from heart ventricles at indicated time points (n = 6 per group, ∼1000 cTnT+ cells per sample). (C) Quantification of total number of
cardiomyocyte isolated from heart ventricles at indicated time points (n = 4–9 per group). (D) Representative images of isolated cardiomyocytes from P5 heart
ventricles and quantification of the percentage of mononucleated (Mono-CM) and binucleated (Bi-CM) cardiomyocytes (n = 4–6 per group, ∼1000 cTnT+ cells per
sample). Arrows point to Bi-CM. cTnT (blue). DAPI (gray). (E,F) The frequency distribution (E) and mean square areas (F) of the surface area of cardiomyocytes
isolated from αMHC-PPARα transgenic and wild-type (WT) heart ventricles at P5. (G) Quantification of genes associated with cardiomyocyte maturation by qRT-PCR
analysis of the mRNA of isolated heart ventricles at P5 (n = 4–5 per group). (H,I) Immunostaining (H) and quantification (I) of TUNEL (green) and DAPI (blue) in P5
heart sections. The images in the second row are the enlargement of the bracketed regions shown in the top row. P value was calculated using Student’s t-test
(A,F,G,I) and one-way ANOVA (B–D).
previously established transgenic mouse line, in which PPARα
is overexpressed specifically in cardiomyocytes (αMHC-PPARα)
(Finck et al., 2002). qRT-PCR analysis confirmed high level
expression of PPARα and its target genes associated with
fatty acid metabolism in P5 hearts (Figure 6A). Consistent
with the findings observed with the GW7647 treatment,
αMHC-PPARα mice showed increases in the number of
EdU+/cTnT+ cells and the total number of cardiomyocytes
in the P4 hearts (Figures 6B,C). By P7, the number of
EdU+/cTnT+ cells in the αMHC-PPARα heart was significantly
lower than that in the wild-type littermate (Figure 6B), and
the total number of cardiomyocytes was similar between
αMHC-PPARα heart and wild-type control (Figure 6C).
Furthermore, αMHC-PPARα transgenic hearts at P5 exhibited
enhanced cardiomyocyte hypertrophic growth and maturation,
as evidenced by the significant increases in the percentage of
binucleated cardiomyocytes and cell size (Figures 6D–F), as
well as by the significant decreases in the expression of fetal
cardiomyocyte program genes (Myh7, Gata4, Mef2c, Nkx2.5)
compared with wild-type controls (Figure 6G). Cell apoptosis
was not significantly changed in GW7647-treated and αMHC-
PPARα animals compared to the control animals as determined
by TUNEL staining on heart sections (Figures 6H,I).
Together, these findings indicated that activation of
PPARα-mediated fatty acid β-oxidation in infant mouse
heart initially increased cardiomyocyte proliferation rate by
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FIGURE 7 | Effects of fatty acid oxidation on cardiomyocyte proliferation in infant mice. (A,B) Quantification of postnatal cardiomyocyte DNA synthesis and cell
number expansion in mice with either GW7647, ETO or saline treatment. (C) The graphs depict the changes in cardiomyocyte proliferation, hypertrophic growth and
maturation based on data obtained by DNA synthesis and cell counting analysis (Figures 3D–E, 5B–G).
inducing more numbers of cardiomyocytes to enter the cell cycle
and proliferate. As the cell cycle proceeded, PPARα-mediated
fatty acid β-oxidation promoted cardiomyocyte enlargement
(hypertrophic growth), maturation and, eventually, generated
bi-nucleated cardiomyocytes. This accelerated cell hypertrophic
growth and maturation induced by activation of fatty acid
β-oxidation reduced cardiomyocyte proliferation, which
ultimately resulted in no change in the total number of
cardiomyocytes in P7 hearts.
An Integrated Model of Fatty Acid
β-Oxidation Effects on Cardiomyocyte
Proliferation in Infant Mouse Heart
Based on our data obtained by design-based stereology and
by EdU labeling and cell counting analysis (Figures 5B,C),
we established a quantitative model of DNA synthesis and
total cell numbers in infant cardiomyocytes (Figures 7A,B).
Inhibition of PPARα-mediated fatty acid β-oxidation delayed
cardiomyocyte cell cycle exit. This was accompanied by
decreased cardiomyocyte hypertrophic growth and maturation
(Figure 7C). By contrast, in response to PPARα-mediated
fatty acid β-oxidation, cardiomyocytes proliferation rate initially
increased, reaching a maximum at P4 (Figures 7A,C). This
was followed by accelerated cardiomyocyte hypertrophic growth
and maturation induced by fatty acid β-oxidation, which led to
cell cycle exit. As a consequence, activation of PPARα-mediated
fatty acid β-oxidation does not alter the total number of
cardiomyocytes in infant mice (Figure 7B).
DISCUSSION
Bioenergetic balance is a critical aspect for flawless operation
of various biological systems and cellular processes. In this
study, we have characterized an essential role for cardiac energy
metabolism in regulating cardiomyocyte growth during early
postnatal life. Cell proliferation, differentiation and metabolism
maturation are three fundamental features of mammals.
Interestingly, cell proliferation and metabolism have both been
implicated in other biological processes such as regulation of
pluripotent stem cell state and T cell activation in immune
system (Cho et al., 2006; Chung et al., 2007, 2010; Gubser
et al., 2013; Assmann and Finlay, 2016). Our findings go
beyond association of proliferation with metabolic changes. We
showed that the shift from glycolysis to fatty acid oxidation
during postnatal life regulates cardiomyocytes proliferation and
hypertrophic growth.
Opposite to what happened in embryonic hearts, which
consume primarily glucose, fatty acids become the major fuel
for ATP synthesis in cardiomyocytes of adult hearts (Lopaschuk
and Jaswal, 2010). Cardiomyocytes proliferate rapidly during
fetal life but lose their ability to proliferation soon after birth
(Ahuja et al., 2007). However, before terminal withdrawal
from the cell cycle, cardiomyocytes undergo another round
of cell cycle during early postnatal life in mice, resulting in
binucleated cardiomyocytes and increased cell size. Notably,
those changes coincide with the metabolic shift from glycolysis
to fatty acid β-oxidation. How and whether cardiac metabolic
switch from glycolysis to fatty acid β-oxidation contributes
to the cardiomyocyte proliferation and hypertrophic growth
in normal development and physiology settings remained
unanswered. Earlier studies demonstrated that in the early
newborn period, the heart relies predominantly on glycolysis and
lactate oxidation as sources of ATP (Lopaschuk and Spafford,
1990; Li et al., 1996; Makinde et al., 1998). Fatty acid β-oxidation
rates remain low, providing less than 15% of the heart’s ATP
requirements, due in part to an inhibition of mitochondrial
fatty acid uptake (Lopaschuk et al., 1991; Li et al., 1997b).
However, within days of neonatal life, a dramatic increase in
fatty acid β-oxidation with a parallel decrease in glycolytic
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rates occur. By P7, glycolysis decreases further and provides
less than 10% of total ATP production5. Thus, to meet the
rigors of postnatal life, the heart undergoes a neonatal metabolic
maturation that involves a switch concordant with a dramatic
increase in mitochondrial functional capacity (Marin-Garcia
et al., 2000; Lai et al., 2008). In this regard, we showed
that, myocardial metabolic switch from glycolysis to fatty acid
β-oxidation occurred within 5 days after birth and coincided
with the burst of cardiomyocyte cell cycle reactivation and
hypertrophic growth.
We found that ETO-mediated inhibition of fatty acid
β-oxidation in infant mouse heart from postnatal days 2 to
4 maintained the capability of cardiomyocyte proliferation,
prevented cardiomyocyte hypertrophic growth and maturation
in the infant mouse hearts at P5 and P7. However, those
effects of ETO waned over time, as seen by the similar level
of cardiomyocyte cell cycle activity, cell size and maturation
in the hearts at weaning age. These data suggest that ETO-
mediated inhibition of fatty acid β-oxidation in infant mouse
heart delayed cardiomyocyte cell cycle exit, hypertrophic
growth and maturation. Previous studies have suggested the
close association of cardiomyocyte cell cycle exit and cell
maturation during postnatal life (Jonker et al., 2010; Paradis
et al., 2014). Thus, the higher proliferating index in P5
and P7 hearts could be attributed to delayed cardiomyocyte
maturation induced by ETO-mediated inhibition of fatty
acid β-oxidation.
We found that activation of PPARα-mediated fatty acid
β-oxidation initially enhanced cardiomyocyte proliferation in
infant mice. Activation of PPARα-mediated fatty acid β-oxidation
led to a higher rate on G0/G1 cell cycle entry and cardiomyocyte
hyperplasia at P4. However, those observations were absent
at P2 and P5. Previous reports from several research groups
as well as our data showed that glycolysis is the major
contributor to energy production in P1-P2 hearts (Lopaschuk
and Spafford, 1990; Lopaschuk et al., 1991; Lopaschuk and Jaswal,
2010). Studies on isolated newborn hearts have shown that
perfusion of neonatal heart under conditions optimal for fatty
acid oxidation (palmitate) did not increase the contribution of
fatty acid oxidation to overall energy production (Lopaschuk
and Spafford, 1990; Lopaschuk et al., 1991), suggesting that
metabolic machinery is not yet mature enough to use fatty
acid as energy substrates for newborn heart. Thus, non-
response to PPARα agonist in P2 heart may be due to lack
of mature metabolic machinery. In addition, we found that
activation of PPARα-mediated fatty acid β-oxidation in infant
mouse heart promoted cardiomyocyte hypertrophic growth,
maturation and generated binucleated cardiomyocytes at P5.
Cardiomyocyte maturation has been shown to be closely
associated with cell cycle exit, which is indicated by cytokinesis
failure and cardiomyocyte binucleation during postnatal life
(Jonker et al., 2010; Paradis et al., 2014). Thus, the quick
drop in the proliferating index in P5 hearts may be caused
by accelerated cardiomyocyte maturation induced by fatty
acid β-oxidation.
Our results held one surprise that ran contrary to the
conventional thinking on the fatty acid β-oxidation on
cardiomyocyte proliferation. Studies of reactive oxygen
species (ROS)-induced cardiomyocyte cell cycle arrest
have suggested a reduction of mitochondrial-dependent
oxidative stress as a strategy to promote cardiomyocyte
proliferation (Puente et al., 2014). We found that activation of
PPARα-mediated fatty acid β-oxidation initially promoted
cardiomyocyte proliferation rate in infant mice. As the
cell cycle proceeded, activation of PPARα-mediated fatty
acid β-oxidation promoted cardiomyocytes hypertrophic
growth, maturation and, eventually, generated binucleated
cardiomyocytes. This accelerated cell hypertrophic growth
and maturation induced by fatty acid β-oxidation reduced
cardiomyocyte proliferation. As a consequence, activation of
PPARα-mediated fatty acid β-oxidation did not alter the total
number of cardiomyocytes in infant mice.
In summary, the current findings indicate that fatty acid
β-oxidation plays an essential role in facilitating cardiomyocyte
proliferation and hypertrophic growth in infant mouse heart.
The infant mouse model represents a useful tool for modulation
of metabolic pathways and for understanding the complex
cellular and molecular mechanisms that dictate cardiomyocyte
growth capacity.
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